Journal article · 2023 · Open access

P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?

D. Patil, E Oehrlein

Value in Health, 26(6), S9 · Published 1 June 2023 · DOI 10.1016/j.jval.2023.03.052

Open PDFView at the publisherCite this paper

In brief

“P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” is a 2023 journal article by D. Patil and E Oehrlein, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access: the full text is free to read at Value in Health.

Citations
0
Authors
2

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Patil, D., & Oehrlein, E. (2023). P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022? Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.052

MLA 9

Patil, D., and E Oehrlein. “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” Value in Health, vol. 26, no. 6, 2023, p. S9. https://doi.org/10.1016/j.jval.2023.03.052.

Chicago

Patil, D. and E Oehrlein. 2023. “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?” Value in Health 26 (6): S9. https://doi.org/10.1016/j.jval.2023.03.052.

Harvard

Patil, D. and Oehrlein, E. (2023) ‘P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?’, Value in Health, 26(6), p. S9. doi:10.1016/j.jval.2023.03.052.

IEEE

D. Patil and E. Oehrlein, “P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?,” Value in Health, vol. 26, no. 6, p. S9, 2023, doi: 10.1016/j.jval.2023.03.052.

BibTeX

@article{patil2023consider,
  title     = {{P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022?}},
  author    = {Patil, D. and Oehrlein, E},
  journal   = {Value in Health},
  year      = {2023},
  volume    = {26},
  number    = {6},
  pages     = {S9},
  doi       = {10.1016/j.jval.2023.03.052},
  url       = {https://doi.org/10.1016/j.jval.2023.03.052}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions

  • patient experience data
  • FDA regulatory decision
  • drug approval
  • patient-reported outcomes
  • regulatory decision-making
  • drug approval trends

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Patil, D., & Oehrlein, E. (2023). P40 How Did FDA Consider Patient Experience Data in Regulatory Decisions Among Approved Drugs in 2022? Value in Health, 26(6), S9. https://doi.org/10.1016/j.jval.2023.03.052

How many times has this paper been cited?

0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Value in Health: sign in and open the PDF from this page.

Who wrote this paper?

D. Patil, E Oehrlein.

What is the DOI of this paper?

10.1016/j.jval.2023.03.052, permanently at https://doi.org/10.1016/j.jval.2023.03.052. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.